SCHEMBL5537671

SCHEMBL5537671

[O]c1ccc(-n2nc3ccccc3n2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.67
HPGD P15428 7/20 0.67
HTT P42858 1/20 0.57
NPC1 O15118 10/20 0.46
RAB9A P51151 10/20 0.46
ALDH1A1 P00352 10/20 0.46
MAPT P10636 7/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
STAT1 P42224 1/20 0.46
PARP1 P09874 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.39
GAA P10253 3/20 0.39
HSD17B10 Q99714 3/20 0.39
POLB P06746 2/20 0.39
TP53 P04637 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
LMNA P02545 2/20 0.39
BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL459011 0.80 KDM4E (1.00) KDM4EHPGDHTTNPC1RAB9A
SCHEMBL11542701 0.77 KDM4E (0.67) KDM4EHPGDHTTNPC1RAB9A
SCHEMBL28395544 0.77 KDM4E (0.74) KDM4EHPGDHTTNPC1RAB9A
SCHEMBL8995917 0.77 KDM4E (0.67) KDM4EHPGDHTTNPC1RAB9A
SCHEMBL19794402 0.77 KDM4E (0.67) KDM4EHPGDHTTNPC1RAB9A
SCHEMBL19993879 0.77 KDM4E (0.67) KDM4EHPGDHTTNPC1RAB9A
SCHEMBL2670040 0.77 KDM4E (0.67) KDM4EHPGDHTTNPC1RAB9A
SCHEMBL1619956 0.77 KDM4E (0.67) KDM4EHPGDHTTNPC1RAB9A
SCHEMBL5187723 0.77 KDM4E (0.59) KDM4EHPGDHTTNPC1RAB9A
SCHEMBL22653490 0.76 KDM4E (0.64) KDM4EHPGDHTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4E 4854/4885HPGD 3159/4885HTT 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.